Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: TOL2506
DRUG: Tamoxifen
DRUG: Letrozole tablets
DRUG: Anastrozole Tablets
DRUG: Exemestane Tablets

Sponsor

Tolmar Inc.